Table 2.
Parameter estimates for linear latent growth models for opioid-positive samples at baseline and 4 weeks of treatment, with Addiction Severity-Lite domain composite scores as predictors.
| Independent variable | Dependent variable | Unstandardized estimate (B) | 95% CI | P-value | |
|---|---|---|---|---|---|
| Model 2: Total sample |
|||||
| --- | UA intercept | .77 | −1.22, 2.75 | .45 | |
| --- | UA slope | .87 | .22, 1.52 | .01 | |
| Sex | UA intercept | −.09 | −.64, .45 | .74 | |
| Trial arm | UA intercept | .54 | .03, 1.05 | .04 | |
| Age (years) | UA intercept | −.04 | −.09, .01 | .12 | |
| Medical*sex | UA intercept | −2.04 | −3.95, −.20 | .03 | |
| Employment*sex | UA intercept | .02 | −1.60, 1.64 | .98 | |
| Alcohol*sex | UA intercept | 1.48 | −4.81, 7.62 | .66 | |
| Drug*sex | UA intercept | 5.93 | −2.94, 14.79 | .19 | |
| Legal*sex | UA intercept | −.98 | −4.93, 2.97 | .63 | |
| Psychological*sex | UA intercept | 1.06 | −1.67, 3.79 | .45 | |
| Family/social*sex | UA intercept | −2.75 | −5.48, −.03 | .05 | |
| Sex | UA slope | .13 | −.01, .27 | .07 | |
| Trial arm | UA slope | −.23 | −.36, −.10 | <.001 | |
| Age (years) | UA slope | −.01 | −.02, .01 | .33 | |
| Medical*sex | UA slope | .63 | .17, 1.10 | .01 | |
| Employment*sex | UA slope | .31 | −.08, .70 | .12 | |
| Alcohol*sex | UA slope | −1.13 | −3.22, .97 | .29 | |
| Drug*sex | UA slope | −1.38 | −3.44, .67 | .19 | |
| Legal*sex | UA slope | −.64 | −1.67, .40 | .23 | |
| Psychological*sex | UA slope | −.65 | −1.35, .05 | .07 | |
| Family/social*sex | UA slope | .31 | −.27, .88 | .30 | |
| UA intercept | UA slope | −.12 | −.20, −.05 | .001 |
ASI-L composite scores were included in the model to define the interaction terms. Interaction terms are denoted with an * between variables names. Buprenorphine/naloxone tapering groups were coded as −.5 = 7-day taper group (referent group), .5 = 28-day taper group, and sex was coded as −.5 = male (referent group), .5 = female; ASI-L composite scores were grand-mean centered.